Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study.

@article{Verfaille2007OralLV,
  title={Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study.},
  author={Christel J Verfaille and Fr{\'e}d{\'e}ric P. Vanhoutte and Claudine Blanchet-Bardon and Maurice A. M. van Steensel and Peter M. Steijlen},
  journal={The British journal of dermatology},
  year={2007},
  volume={156 5},
  pages={965-73}
}
BACKGROUND Liarozole, a retinoic acid metabolism blocking agent, has been granted orphan drug status for congenital ichthyosis by the European Commission and the U.S. Food and Drug Administration. OBJECTIVES The purpose of this trial was to investigate the efficacy, tolerability and safety of oral liarozole vs. acitretin in patients with ichthyosis. METHODS In this double-blind comparative trial of liarozole vs. acitretin, 32 patients with ichthyosis were randomized to be treated with… CONTINUE READING